Literature DB >> 9059343

Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer.

D C Talbot1, P D Brown.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 9059343     DOI： 10.1016/s0959-8049(96)00398-x

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  29 in total

Review 1.  The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer.

Authors:  G Cox; W P Steward; K J O'Byrne
Journal:  Thorax       Date:  1999-02       Impact factor: 9.139

2.  The role of the vascular phase in solid tumor growth: a historical review.

Authors:  D Ribatti; A Vacca; F Dammacco
Journal:  Neoplasia       Date:  1999-10       Impact factor: 5.715

3.  Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis.

Authors:  G Bergers; R Brekken; G McMahon; T H Vu; T Itoh; K Tamaki; K Tanzawa; P Thorpe; S Itohara; Z Werb; D Hanahan
Journal:  Nat Cell Biol       Date:  2000-10       Impact factor: 28.824

Review 4.  Matrix metalloproteinase inhibitors: present achievements and future prospects.

Authors:  L J Denis; J Verweij
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

5.  Sustained Release of a Peptide-Based Matrix Metalloproteinase-2 Inhibitor to Attenuate Adverse Cardiac Remodeling and Improve Cardiac Function Following Myocardial Infarction.

Authors:  Zhaobo Fan; Minghuan Fu; Zhaobin Xu; Bo Zhang; Zhihong Li; Haichang Li; Xinyu Zhou; Xuanyou Liu; Yunyan Duan; Pei-Hui Lin; Pu Duann; Xiaoyun Xie; Jianjie Ma; Zhenguo Liu; Jianjun Guan
Journal:  Biomacromolecules       Date:  2017-08-07       Impact factor: 6.988

6.  Augmented anti-metastatic efficacy of a selective matrix metalloproteinase inhibitor, MMI-166, in combination with CPT-11.

Authors:  Hideo Maki; Kanji Hojo; Hidekazu Tanaka; Takuko Yamada Sawada; Ryuji Maekawa; Takayuki Yoshioka
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

Review 7.  Anti-angiogenic treatment strategies for malignant brain tumors.

Authors:  M Kirsch; G Schackert; P M Black
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

8.  Anti-metastatic efficacy and safety of MMI-166, a selective matrix metalloproteinase inhibitor.

Authors:  R Maekawa; H Maki; T Wada; H Yoshida; K Nishida-Nishimoto; H Okamoto; Y Matsumoto; H Tsuzuki; T Yoshioka
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

9.  Matrix metalloproteinase-9-mediated tissue injury overrides the protective effect of matrix metalloproteinase-2 during colitis.

Authors:  Pallavi Garg; Matam Vijay-Kumar; Lixin Wang; Andrew T Gewirtz; Didier Merlin; Shanthi V Sitaraman
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-02       Impact factor: 4.052

10.  Matrix metalloproteinase inhibitor, MMI270 (CGS27023A) inhibited hematogenic metastasis of B16 melanoma cells in both experimental and spontaneous metastasis models.

Authors:  Tatsuhiko Kasaoka; Hiroko Nishiyama; Mikiko Okada; Motowo Nakajima
Journal:  Clin Exp Metastasis       Date:  2008-07-31       Impact factor: 5.150
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.